SCHEMBL10304952

SCHEMBL10304952

CCOc1nc(-c2ccccc2C)cnc1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 2/20 0.48
PRKDC P78527 1/20 0.48
GAA P10253 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HEXA P06865 1/20 0.41
HEXB P07686 1/20 0.41
PIK3CA P42336 1/20 0.41
TLR8 Q9NR97 2/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CSF1R P07333 2/20 0.39
CD274 Q9NZQ7 2/20 0.37
PDCD1 Q15116 1/20 0.37
IDO1 P14902 1/20 0.37
METAP2 P50579 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10305052 0.85 ATR (0.50) ATRPRKDCPIK3CACD274PDCD1
SCHEMBL13575901 0.83 ATR (0.44) ATRPRKDCHEXAHEXBPIK3CA
SCHEMBL10304959 0.81 ABL1 (0.45) PIK3CAGRM5
SCHEMBL10305106 0.80 MAPT (0.40) PIK3CATLR8SMN1; SMN2CSF1RALDH1A1
SCHEMBL28174453 0.79 ATR (0.56) ATRPRKDCHEXAHEXBTLR8
SCHEMBL10305022 0.79 HEXA (0.54) ATRPRKDCHEXAHEXBTLR8
SCHEMBL3769692 0.79 NOS1 (0.44) ATRPRKDCHEXAHEXBNPC1
SCHEMBL10304977 0.76 CSF1R (0.39) GAAPIK3CACSF1RALDH1A1HSD17B10
SCHEMBL17204032 0.75 ATR (0.52) ATRPRKDCHEXAHEXBTLR8
SCHEMBL10304956 0.73 SQOR (0.46) ATRPRKDCGAAL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264770-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-18 US disclosed
US-20120172321-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264770-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 ATR 2875/4885PRKDC 894/4885GAA 221/4885
US-20120172321-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 ATR 2875/4885PRKDC 894/4885GAA 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.